Bevacizumab (Avastin) in the treatment of patients with breast cancer
We consider the possibility of bevacizumab (Avastin) use in the treatment of disseminated breast cancer (BC). The clinical studies show the high bevacizumab efficacy in treatment of patients with HER2-negative breast cancer. Available data for the effectiveness of the combination of endocrine therapy and bevacizumab require further study in phase III trials. The results of active ongoing phase III studies examining the feasibility of bevacizumab in patients with HER2-positive breast cancer in combination with trastuzumab and chemotherapy are of the utmost interest.

Keywords: trastuzumab, anthracyclines, taxanes, bevacizumab, disseminated breast cancer, endocrine therapy